FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

						_														
1. Name and Address of Reporting Person*  JANTZ DEREK						2. Issuer Name and Ticker or Trading Symbol PRECISION BIOSCIENCES INC [ DTIL ]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
														X	Director			10% Ov	vner	
(Last) (First) (Middle)						3. Date of Earliest Transaction (Month/Day/Year)								X	below)	•		Other (s below)	specify	
C/O PRECISION BIOSCIENCES, INC.						02/18/2021									Chief Scientific Officer					
302 E. PETTIGREW STREET, SUITE A-100																				
(Street)						4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)					
DURHAM NC 27701															X Form filed by One Reporting Person  Form filed by More than One Reporting					
				-										Person		e than	One Repoi	rting		
(City)	(S		(Zip)																	
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned  1. Title of Security (Instr. 3)  2. Transaction  2. Deemed  3.  4. Securities Acquired (A) or  5. Amount of  6. Ownership  7. Nature																			
1. Title of Security (Instr. 3)  2. Transact Date (Month/Dat						ar) li	Execution if any	med on Date, Day/Year)	3. Transaction Code (Instr. 8)			es Acquired (A) or Of (D) (Instr. 3, 4 an		id 5)	Securitie Beneficia Owned F	es ally Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		of Indirect Beneficial Ownership	
									Code	v	Amount	(A) or (D)	Price		Reported Transact (Instr. 3 a	ion(s)			(Instr. 4)	
Common Stock 02/18/2						.021			M		21,514	A	\$0.	.04	3,92	8,859		D		
Common Stock 02/18/2						2021					6,871	D	\$12	2.2	3,92	1,988		D		
Common Stock 02/19/2					9/2021	2021					21,514	A \$0		.04	3,943,502			D		
Common Stock 02/19/2						2021					9,663	D \$11.55		55 <sup>(2)</sup>	3,933,839			D		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															<u> </u>					
	-	I				cal	_		•					_			_		T	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deem Execution if any (Month/Da	n Date,	4. Transactio Code (Inst 8)		on of		6. Date Exerci Expiration Dat (Month/Day/Ye		te	7. Title and Amoun of Securities Underlying Derivative Security (Instr. 3 and 4)		[	3. Price of Derivative Security Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4		11. Nature of Indirect Beneficial Ownership (Instr. 4)	
													Amou	1						
					Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	Numb of Share							
Employee					50ue	Ė	1(7)	(5)					Silare	+					<del>                                     </del>	
Stock Option (Right to Buy)	\$0.04	02/18/2021			M			21,514	(3)		05/17/2021	Common Stock	21,51	14	\$0.00	236,65	4	D		
Employee Stock Option (Right to Buy)	\$0.04	02/19/2021			М			21,514	(3)		05/17/2021	Common Stock	21,51	14	\$0.00	215,14	0	D		

## **Explanation of Responses:**

- 1. All sales were effected pursuant to a Rule 10b5-1 plan. The transaction was a sell-to-cover exercise, with shares sold to cover the option exercise price and taxes, and the reporting person retaining all remaining shares.
- 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$11.53 to \$11.61. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- 3. The option is fully vested and exercisable.

## Remarks:

/s/ Dario Scimeca, Attorney-in-Fact for Derek Jantz

\*\* Signature of Reporting Person

02/22/2021

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.